Please login to the form below

Not currently logged in
Email:
Password:

FDA warns Pfizer over adverse reporting

The US FDA has issued Pfizer with a warning letter relating to failures to report adverse events correctly

The US Food and Drug Administration (FDA) has issued Pfizer with a warning letter relating to failures to report adverse events correctly.

The letter, sent to Pfizer on May 26, follows an inspection of the company's New York premises by the US agency, which took place over a period of several weeks almost a year ago.

The inspection was to check Pfizer's procedures for conforming to the FDA's rules that adverse events must be reported to the authority within 15 days.

The letter contained reference to several instances where the pharma giant did not report adverse events relating to Lipitor (atorvastatin calcium) and Lyrica (pregabalin) at all. Further issues included the failure to report issues of visual disturbances as a result of a patient taking Viagra (sildenafil citrate) within the specified 15 day time period.

The US regulator also accused Pfizer of downgrading the classification of some reported events without justification.

In April 2010, the FDA warned Pfizer over its Geodon trials.

10th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics